These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106. Correction: A randomized controlled trial of an online health tool about Down syndrome. Chung J; Donelan K; Macklin EA; Schwartz A; Elsharkawi I; Torres A; Hsieh YG; Parker H; Lorenz S; Patsiogiannis V; Santoro SL; Wylie M; Clarke L; Estey G; Baker S; Bauer PE; Bull M; Chicoine B; Cullen S; Frey-Vogel A; Gallagher M; Hasan R; Lamb A; Majewski L; Mast J; Riddell T; Sepucha K; Skavlem M; Skotko BG Genet Med; 2021 Jan; 23(1):236. PubMed ID: 33169000 [No Abstract] [Full Text] [Related]
107. DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature. Meissner LE; Macnamara EF; D'Souza P; Yang J; Vezina G; ; Ferreira CR; Zein WM; Tifft CJ; Adams DR Mol Genet Genomic Med; 2020 Dec; 8(12):e1544. PubMed ID: 33159716 [TBL] [Abstract][Full Text] [Related]
108. Mitochondrial DNA copy number in human disease: the more the better? Filograna R; Mennuni M; Alsina D; Larsson NG FEBS Lett; 2021 Apr; 595(8):976-1002. PubMed ID: 33314045 [TBL] [Abstract][Full Text] [Related]
110. A Mitochondrial DNA Variant Elevates the Risk of Gallstone Disease by Altering Mitochondrial Function. Sun D; Niu Z; Zheng HX; Wu F; Jiang L; Han TQ; Wei Y; Wang J; Jin L Cell Mol Gastroenterol Hepatol; 2021; 11(4):1211-1226.e15. PubMed ID: 33279689 [TBL] [Abstract][Full Text] [Related]
111. Novel insights from fetal and placental phenotyping in 3 mouse models of Down syndrome. Adams AD; Hoffmann V; Koehly L; Guedj F; Bianchi DW Am J Obstet Gynecol; 2021 Sep; 225(3):296.e1-296.e13. PubMed ID: 33766516 [TBL] [Abstract][Full Text] [Related]
112. From the lab to the people: major challenges in the biological treatment of Down syndrome. Rondal JA AIMS Neurosci; 2021; 8(2):284-294. PubMed ID: 33709029 [TBL] [Abstract][Full Text] [Related]
113. The Role of Oxidative Stress in Trisomy 21 Phenotype. Buczyńska A; Sidorkiewicz I; Krętowski AJ; Zbucka-Krętowska M Cell Mol Neurobiol; 2023 Nov; 43(8):3943-3963. PubMed ID: 37819608 [TBL] [Abstract][Full Text] [Related]
114. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Galbraith MD; Rachubinski AL; Smith KP; Araya P; Waugh KA; Enriquez-Estrada B; Worek K; Granrath RE; Kinning KT; Paul Eduthan N; Ludwig MP; Hsieh EWY; Sullivan KD; Espinosa JM Sci Adv; 2023 Jun; 9(26):eadg6218. PubMed ID: 37379383 [TBL] [Abstract][Full Text] [Related]
115. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Waugh KA; Minter R; Baxter J; Chi C; Galbraith MD; Tuttle KD; Eduthan NP; Kinning KT; Andrysik Z; Araya P; Dougherty H; Dunn LN; Ludwig M; Schade KA; Tracy D; Smith KP; Granrath RE; Busquet N; Khanal S; Anderson RD; Cox LL; Estrada BE; Rachubinski AL; Lyford HR; Britton EC; Fantauzzo KA; Orlicky DJ; Matsuda JL; Song K; Cox TC; Sullivan KD; Espinosa JM Nat Genet; 2023 Jun; 55(6):1034-1047. PubMed ID: 37277650 [TBL] [Abstract][Full Text] [Related]
116. Application of regulation of reactive oxygen species and lipid peroxidation to disease treatment. Shichiri M; Suzuki H; Isegawa Y; Tamai H J Clin Biochem Nutr; 2023 Jan; 72(1):13-22. PubMed ID: 36777080 [TBL] [Abstract][Full Text] [Related]
117. Visual discrimination and inhibitory control deficits in mouse models of Down syndrome: A pilot study using rodent touchscreen technology. Siegel AE; Bianchi DW; Guedj F J Neurosci Res; 2023 Apr; 101(4):492-507. PubMed ID: 36602162 [TBL] [Abstract][Full Text] [Related]
118. IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome. Araya P; Kinning KT; Coughlan C; Smith KP; Granrath RE; Enriquez-Estrada BA; Worek K; Sullivan KD; Rachubinski AL; Wolter-Warmerdam K; Hickey F; Galbraith MD; Potter H; Espinosa JM Cell Rep; 2022 Dec; 41(13):111883. PubMed ID: 36577365 [TBL] [Abstract][Full Text] [Related]
119. Studies on Apigenin and Its Biological and Pharmacological Activity in Brain Disorders. Kumar V; Kundu S Adv Pharm Bull; 2022 Aug; 12(4):645-648. PubMed ID: 36415642 [No Abstract] [Full Text] [Related]
120. The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives. Stagni F; Bartesaghi R Front Cell Neurosci; 2022; 16():903729. PubMed ID: 35634470 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]